Log In
Print this Print this

PNT100, PNT2258

  Manage Alerts
Collapse Summary General Information
Company ProNAi Therapeutics Inc.
DescriptionCancer therapeutic targeting DNA sequence upstream of B cell lymphoma 2 (BCL-2; BCL2) promoters
Molecular Target B cell lymphoma 2 (BCL-2) (BCL2)
Mechanism of ActionBcl-2 inhibitor; Gene silencing
Therapeutic ModalityNucleic acid: Linear DNA

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today